Target Name: PRRT3
NCBI ID: G285368
Other Name(s): PRRT3 variant 1 | Proline-rich transmembrane protein 3 (isoform 1) | PRRT3_HUMAN | Proline rich transmembrane protein 3, transcript variant 1 | Proline-rich transmembrane protein 3 | proline rich transmembrane protein 3

PRRT3: A Protein Involved in Neurodegenerative Diseases

PRRT3 (PRMT3) is a protein that is expressed in the brain and is known for its role in the development and progression of neurodegenerative diseases. The protein is composed of 1,942 amino acids and has a molecular weight of 21.9 kDa. It is a member of the PRMT family, which includes a variety of proteins that are involved in the regulation of DNA methylation.

One of the unique features of PRRT3 is its ability to interact with the histone methyltransferase SMMT2. This interaction allows PRRT3 to modulate the level of methylation at the promoter of a gene, which can have a significant impact on the gene's expression.

In neurodegenerative diseases, including Alzheimer's and Parkinson's diseases, the misregulation of PRMT3 has been implicated in the development and progression of the diseases. This is because the levels of methylation at the promoter of these genes are often increased, which can lead to the activation of genes that are involved in the pathology of the disease.

One potential drug target for PRRT3 is the use of histone deacetylases (HDACs), which are enzymes that remove methyl groups from the histone proteins. By inhibiting the activity of HDACs, it may be possible to reduce the level of methylation at the promoter of a gene and potentially reduce the risk of neurodegenerative diseases.

Another potential drug target for PRRT3 is the use of DNA methylation drugs, such as 5-azacidisindole (5-ASI) and SBS-3536. These drugs work by binding to the enzyme PRMT2 and inhibiting its activity, which can lead to the removal of methyl groups from the promoter of a gene and potentially reduce the risk of neurodegenerative diseases.

In conclusion, PRRT3 is a protein that is involved in the regulation of DNA methylation and has been implicated in the development and progression of neurodegenerative diseases. The use of HDACs and DNA methylation drugs may be a promising strategy for the development of new treatments for these diseases. Further research is needed to fully understand the role of PRRT3 in neurodegenerative diseases and to develop effective treatments.

Protein Name: Proline Rich Transmembrane Protein 3

More Common Targets

PRRT3-AS1 | PRRT4 | PRRX1 | PRRX2 | PRSS1 | PRSS12 | PRSS16 | PRSS2 | PRSS21 | PRSS22 | PRSS23 | PRSS27 | PRSS3 | PRSS30P | PRSS33 | PRSS35 | PRSS36 | PRSS37 | PRSS38 | PRSS3P1 | PRSS3P2 | PRSS3P3 | PRSS40A | PRSS41 | PRSS42P | PRSS45P | PRSS46P | PRSS48 | PRSS50 | PRSS53 | PRSS54 | PRSS55 | PRSS56 | PRSS57 | PRSS58 | PRSS59P | PRSS8 | PRTFDC1 | PRTG | PRTN3 | PRUNE1 | PRUNE2 | PRX | PRXL2A | PRXL2B | PRXL2C | PRY | PRY2 | PRYP3 | PRYP4 | PSAP | PSAPL1 | PSAT1 | PSAT1P1 | PSAT1P3 | PSCA | PSD | PSD2 | PSD3 | PSD4 | PSEN1 | PSEN2 | PSENEN | PSG1 | PSG10P | PSG11 | PSG2 | PSG3 | PSG4 | PSG5 | PSG6 | PSG7 | PSG8 | PSG9 | PSIP1 | PSKH1 | PSKH2 | PSMA1 | PSMA2 | PSMA3 | PSMA3-AS1 | PSMA3P1 | PSMA4 | PSMA5 | PSMA6 | PSMA7 | PSMA8 | PSMB1 | PSMB10 | PSMB11 | PSMB2 | PSMB3 | PSMB3P2 | PSMB4 | PSMB5 | PSMB6 | PSMB7 | PSMB7P1 | PSMB8 | PSMB8-AS1